Shahnaz Shahinfar
Overview
Explore the profile of Shahnaz Shahinfar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
2187
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Levin A, Agarwal R, Herrington W, Heerspink H, Mann J, Shahinfar S, et al.
Kidney Int
. 2020 Oct;
98(4):849-859.
PMID: 32998816
Kidney failure is an important outcome for patients, clinicians, researchers, healthcare systems, payers, and regulators. However, no harmonized international consensus definitions of kidney failure and key surrogates of progression to...
2.
Sohn W, Portale A, Salusky I, Zhang H, Yan L, Ertik B, et al.
Pediatr Nephrol
. 2018 Dec;
34(4):739-740.
PMID: 30536181
The original version of this article unfortunately contained three mistakes. In Table 1, the last line under "Key Inclusion Criteria" should read "Normal or clinically acceptable ECGs at screening and...
3.
Warady B, Iles J, Ariceta G, Dehmel B, Hidalgo G, Jiang X, et al.
Pediatr Nephrol
. 2018 Dec;
34(3):475-486.
PMID: 30506144
Background: This randomized phase 3 study evaluated the efficacy and safety of cinacalcet in children with secondary hyperparathyroidism (SHPT) receiving dialysis. Methods: This study had double-blind and open-label phases. Eligible...
4.
Sohn W, Portale A, Salusky I, Zhang H, Yan L, Ertik B, et al.
Pediatr Nephrol
. 2018 Aug;
34(1):145-154.
PMID: 30141180
Background: Calcimimetics, shown to control biochemical parameters of secondary hyperparathyroidism (SHPT), have well-established safety and pharmacokinetic profiles in adult end-stage renal disease subjects treated with dialysis; however, such studies are...
5.
Webb N, Wells T, Shahinfar S, Massaad R, Dankner W, Lam C, et al.
Clin J Am Soc Nephrol
. 2014 May;
9(8):1441-8.
PMID: 24875194
Background And Objectives: Once-daily losartan reduces BP in a dose-dependent manner and is well tolerated in hypertensive children aged 6-16 years. This study assessed the dose-response relationship, safety, and tolerability...
6.
Sinkeler S, Kwakernaak A, Bakker S, Shahinfar S, Esmatjes E, de Zeeuw D, et al.
Diabetes Care
. 2013 Jan;
36(6):1489-94.
PMID: 23300289
Objective: The creatinine excretion rate (CER) is inversely associated with mortality in the general and renal transplant population. The CER is a marker for muscle mass. It is unknown whether...
7.
Webb N, Shahinfar S, Wells T, Massaad R, Gleim G, McCrary Sisk C, et al.
Pediatr Nephrol
. 2012 Dec;
28(5):737-43.
PMID: 23207876
Background: A previous subgroup analysis of a 12-week, double-blind study demonstrated that losartan significantly lowered proteinuria versus placebo and amlodipine and was well tolerated in children (1-17 years old) with...
8.
Webb N, Shahinfar S, Wells T, Massaad R, Gleim G, Santoro E, et al.
Kidney Int
. 2012 Jun;
82(7):819-26.
PMID: 22739977
Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers delay progression of chronic kidney disease and have antiproteinuric effects beyond their effects on blood pressure. They are routinely used...
9.
Packham D, Alves T, Dwyer J, Atkins R, de Zeeuw D, Cooper M, et al.
Am J Kidney Dis
. 2011 Nov;
59(1):75-83.
PMID: 22051245
Background: Previous studies have shown that patients with chronic kidney disease, including those with diabetic nephropathy, are more likely to die of cardiovascular disease than reach end-stage renal disease (ESRD)....
10.
Miao Y, Ottenbros S, Laverman G, Brenner B, Cooper M, Parving H, et al.
Hypertension
. 2011 Jun;
58(1):2-7.
PMID: 21632472
Emerging data show that increased serum uric acid (SUA) concentration is an independent risk factor for end-stage renal disease. Treatment with the antihypertensive drug losartan lowers SUA. Whether reductions in...